Target- |
MechanismPancrelipase replacements |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date30 Apr 2009 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date15 Dec 2008 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.GB |
First Approval Date01 Jan 1961 |
An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
The purpose of this study is to evaluate the safety and tolerability of Creon micro in children younger than four years with pancreatic exocrine insufficiency.
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Effect of Betahistine on Cerebral Blood Flow and Gait in Subjects at Risk of Falling
Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This placebo-controlled pharmacodynamic treatment study will primarily explore the effect of betahistine on cerebral blood flow measured by dynamic contrast-enhanced MRI imaging, in a patient population with MRI evidence of cerebrovascular compromise. Also it will be measured if CBF changes correlate with gait and cognitive changes.
An Open-Label Study to Determine ADME of 14C Labeled SLV337 After a Single Dose of an Oral Suspension
This is an open-label study to determine the ADME (Absorption, Disposition, Metabolism and Excretion) of 14C labeled SLV337 after a single dose of an oral suspension.
100 Clinical Results associated with Abbott Products LLC
0 Patents (Medical) associated with Abbott Products LLC
100 Deals associated with Abbott Products LLC
100 Translational Medicine associated with Abbott Products LLC